Business

 


Pulmonary Tuberculosis - Pipeline Review, H1 2014

Pulmonary Tuberculosis Drugs Pipeline: New analysis available


Companies & Markets

© companiesandmarkets.com
06.05.2014 17:27:01 - Pulmonary Tuberculosis - Pipeline Review, H1 2014 - a new market research report on companiesandmarkets.com

(live-PR.com) - Pulmonary Tuberculosis - Pipeline Review, H1 2014

Summary

The ´Pulmonary Tuberculosis - Pipeline Review, H1 2014´, provides an overview of the Pulmonary Tuberculosis´s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest

 

updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Tuberculosis and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the analyst team. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Tuberculosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pulmonary Tuberculosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pulmonary Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pulmonary Tuberculosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Tuberculosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pulmonary Tuberculosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Click for report details: www.companiesandmarkets.com/Market/Healthcare-an ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-an ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-an ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Re ..

About Us
Companiesandmarkets.com aims to provide clients with the widest array of reports and market research across all of our 27 industry sectors. Companiesandmarkets.com’s team of analysts are available to offer clients specific advice on finding relevant information and also purchasing the correct market research reports for their specific business needs. Over 100,000 companies are listed in Companiesandmarkets.com´s online reports database, providing clients with an extensive coverage not only of company profiles but also of high value and insightful market reports.


Author:
Mike King
e-mail
Phone: 44 0203 086 8600


 

Disclaimer: If you have any questions regarding information in this article please contact the author. Please do not contact Live-PR.com. We are not able to assist you. Live-PR.com disclaims content contained in this article. Live-PR.com is not authorized to give any information about content and not responsible for content posted by third party.
refer this article
Print This Article